CAU
MLTX icon

Caxton Associates (UK)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Caxton Associates (UK)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,880
Closed -$347K – 826
2025
Q1 		$347K Buy
+8,880
New +$383K 0.01% 588

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Caxton Associates (UK)'s MLTX Position: Q2 2025 in Review

Caxton Associates (UK) sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 8,880 shares — an estimated $347K sold.

Caxton Associates (UK) first reported a position in MLTX in Q1 2025 and held it in 1 quarter. The position peaked at $347K in Q1 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

  • Caxton Associates (UK) reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 8,880 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $347K.
  • Caxton Associates (UK) first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s MoonLake Immunotherapeutics position peaked at $347K in Q1 2025.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Caxton Associates (UK)'s 13F filing for Q2 2025, filed 15 Aug 2025.